Biohaven partners with Ono in $100m IgG degrader deal

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio. The transaction grants Ono exclusive rights for candidates BHV-1300, BHV-1310, and BHV-1320 across Taiwan, South Korea, and Japan. BHV-1300 is an investigational small-molecule degrader currently under evaluation in a Phase III clinical study for Graves’ disease. Credit: SmartPhotoLab/Shutterstock.com. Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan immunoglobulin G (IgG) degrader portfolio. The transaction grants Ono exclusive development and commercialisation rights for…

Salong Debbarma · 2026-10-09

Biohaven has entered into an exclusive regional collaboration and licensing agreement worth up to $100m with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio.

Source: Pharmaceutical Technology